Director, Division of Allergy and Immunology at Cincinnati Children's Hospital Medical Center;
Director, Cincinnati Center for Eosinophilic Disorders
Marc E. Rothenberg (born 1961) is an American physician-scientist who has made significant contributions to the fields of allergy, gastroenterology, and immunology. He is currently a Professor of Pediatrics, at Cincinnati Children's Hospital Medical Center, and the University of Cincinnati College of Medicine, the Director of the Division of Allergy and Immunology, the Director of the Cincinnati Center for Eosinophilic Disorders,[2] and the principal investigator of the Consortium of Eosinophilic Disease Researchers (CEGIR)[3] as part of the Rare Disease Clinical Research Network of the National Institute of Health.[4] Rothenberg's research is focused on eosinophilic gastrointestinal diseases.[5]
Rothenberg was born in New York City in 1961. He received his Bachelor of Arts degree in Biochemistry and Chemistry from Brandeis University in 1983. His undergraduate years were influences by the renowned biochemist Professor William P. Jencks, who was Rothenberg’s early research mentor.[6] He went on to earn his medical degree and PhD in Immunology from Harvard Medical School in 1990, conducting research under the mentorship of Professor K. Frank Austen.[6] He completed his residency in pediatrics at Boston Children's Hospital and his fellowship in Allergy and Immunology and Hematology at Boston Children’s Hospital and the Dana Farber Cancer Institute.[2]
In 2016, Rothenberg was the first recipient of the Denise and Dave Bunning Chair for Allergy and Immunology.[8]
Rothenberg is also the current Director of the NIH-sponsored Consortium of Eosinophilic Gastrointestinal Disease Researchers, part of the Rare Diseases Clinical Research Network.[3] In 2021, he was elected Co-Chair of the RDCRN.[9]
The Rothenberg CURED Laboratory at Cincinnati Children's Hospital Medical Center conducts research focused on the molecular analysisofallergic inflammation, particularly the pathogenesis of eosinophilic gastrointestinal disorders.[10] His research is credited with elucidating the mechanism of eosinophilia, including the identification of key checkpoints that are central targets for therapeutic intervention. These targets have been translated into developed clinical products. Rothenberg's research has included key proof-of-principle studies that provided the bases for a new class of drugs, anti-eosinophil therapeutics, as well as the first FDA approved drug for eosinophilic esophagitis.
